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Transmission routes of PARV4, a newly discovered hu-
man parvovirus, were investigated by determining frequen-
cies of persistent infections using autopsy samples from 
different risk groups. Predominantly parenteral routes of 
transmission were demonstrated by infection restricted to 
injection drug users and persons with hemophilia and ab-
sence of infection in homosexual men with AIDS and low-
risk controls. 
T
he novel human parvovirus PARV4, is a recently 
discovered member of the family Parvoviridae ( 1). 
PARV4 was originally cloned from a sample obtained from 
a person at risk for HIV infection through injection drug 
use or sexual contact who was enrolled in the San Francis-
co-based Option Project cohort. Since the original report, 
PARV4 infections have been detected in samples of pooled 
plasma from a variety of manufacturers (2,3), and at low 
frequency in pooled and individual plasma samples from 
US blood donors (<2%) (3). A higher frequency of PARV4 
viremia found among other persons enrolled in the Option 
Project cohort (6%) (3) and detection of PARV4 in autopsy 
blood from a person with a history of injection drug use (4) 
are indicators of a potential association between PARV4 
infection and high-risk behavior for HIV infection. 
Despite the acute, resolving nature of many parvovirus 
infections, it is now well established that many members 
of the family Parvoviridae, such as the human erythrovi-
rus B19, can establish lifelong persistence with restricted 
replication and absence or rarity of detectable long-term 
viremia (5–7). Using a highly sensitive nested PCR, we re-
cently investigated a range of autopsy tissues taken from 
high-risk persons (HIV-infected with histories of injection 
drug use or male homosexual contact) and low-risk persons 
(uninfected with HIV and hepatitis C virus [HCV]) who did 
not have a history of parenteral exposure or contact with 
multiple sexual partners. We checked for evidence of simi-
lar persistence of PARV4 (8). Remarkably, bone marrow, 
lymphoid tissue, or both from 17 of 24 study subjects in the 
high-risk group were positive for PARV4, but both sample 
types were uniformly negative in low-risk controls. These 
ﬁ  ndings not only conﬁ  rm the ability of PARV4 to establish 
persistent infections in humans, but also the existence of 
shared risk factors with HIV for transmission. 
The Study 
We tested well-deﬁ  ned risk groups for HIV and paren-
terally transmitted infections to more precisely determine 
the transmission route of PARV4. Autopsy tissue samples 
used in this project were obtained from the Edinburgh 
Medical Research Council (MRC) HIV Brain and Tissue 
Bank at the Western General Hospital, Edinburgh. Consent 
for use of postmortem tissue was obtained from the Lothian 
Research Ethics Committee (LREC2002/4/36). Study sub-
jects were divided into 4 groups of approximately equal 
size (n = 11–13, Table 1): 1) injection drug users (IDUs) 
without HIV infection (all positive for antibodies to HCV 
when testing was available); 2) Men who had sex with men 
(MSM) with AIDS without a history of parenteral expo-
sure (all negative for antibodies to HCV when testing was 
available); 3) IDUs infected with HIV with AIDS-deﬁ  ning 
illnesses; and 4) IDUs infected with HIV who died of other 
causes while presymptomatic. 
We also tested samples from 2 persons with hemophilia 
treated with nonvirally inactivated factor VIII concentrates 
from the late 1970s onward, both of whom became infected 
with HIV and HCV. Study subjects showed similar demo-
graphic characteristics, with similar age ranges and dates of 
death largely restricted to the 1990s (Table 1). The IDUs, 
MSM, and patients with hemophilia with AIDS showed 
similar mean CD4 counts before death, indicating profound 
immunosuppression. Samples of lymphoid tissue (lymph 
node or spleen) and bone marrow were assayed for par-
vovirus B19 and PARV4 DNA sequences by nested PCR 
as described (8). In all samples, >0.5 μg of genomic DNA 
was tested, which provided a test sensitivity of ≈6 copies of 
target sequence/106 cells. Detection of both parvovirus B19 
and PARV4 sequences was highly reproducible between 
the 2 tissues analyzed (Table 2), which enabled generally 
unambiguous categorization of study subjects into infected 
and uninfected categories. Persons in whom B19 or PARV4 
was detected in 1 of the 2 tissues were considered infected, 
although the same conclusions for risk group associations 
would have been reached if the 5 persons with discrepant 
results had been excluded from analysis or considered un-
infected (data not shown).
Parvovirus B19 infection frequency increased with age 
of the patients and corresponded closely to frequencies of 
B19 seropositivity in the general population in the United 
Kingdom recorded previously for different age ranges (9). 
Infections were absent in 2 young patients with hemo-
philia (22 and 26 years of age at death), ranged from 46% 
*University of Edinburgh, Edinburgh, Scotland, United Kingdom; 
and †Western General Hospital, Edinburgh, Scotland, United 
Kingdom Human Parvovirus Transmission 
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 9, September 2007  1387 
to 67% in IDUs and MSM (mean ages 33–39 years), and 
were found in all 8 low-risk controls (mean age 54 years). 
These ﬁ  ndings provide further evidence for high frequen-
cies of or potentially universal persistence of infection with 
B19 in those exposed (5–7). In contrast, infections with 
PARV4 were restricted to those with a history of parenteral 
exposure (IDUs and patients with hemophilia). Frequen-
cies of infection ranged from 8.3% (1/12) of the HIV-nega-
tive IDUs to 55% and 85%, respectively, in HIV-infected 
IDUs before and after AIDS developed. Similarly, 1 of the 
2 patients with hemophilia was positive for PARV4. No 
PARV4 infections were found in the MSM group, despite 
profound immunosuppression associated with AIDS and 
histories of frequent past exposure to sexually transmitted 
infections, such as HIV. 
Conclusions
The absence of detectable PARV4 in the MSM group 
demonstrates that PARV4 infections are not speciﬁ  cally 
associated with HIV co-infection. Instead, its speciﬁ  c risk 
group association with injection drug use and hemophilia 
(and absence in MSM and low-risk controls) provides evi-
dence for a predominantly or exclusively parenteral route 
of transmission. The higher frequency of PARV4 detection 
in HIV-positive persons may be an indirect reﬂ  ection of the 
greater degree of parenteral exposure among IDUs who be-
come infected with HIV. In Edinburgh, HIV infections are 
much less prevalent in the IDU population than are HCV 
infections, because the transmission of HIV is less efﬁ  cient 
through the bloodborne route (10). The higher frequency 
of PARV4 infection in the IDU-AIDS group compared 
with the frequency in the pre-AIDS group may also have 
originated through differential parenteral exposure; AIDS 
is more likely to be diagnosed among those exposed early 
to HIV in their period of injection. 
It could be argued that the higher frequency of PARV4 
infection in HIV-infected IDUs and persons with hemo-
philia may be the result of greater ease of detection in 
immunosuppressed persons. PARV4 infections may be 
widespread like B19 infections but may only persist in de-
tectable amounts in persons whose compromised immune 
system allows viral reactivation. Although this hypothesis 
was difﬁ  cult to discount in our original study (8), our new 
observation of an absence of PARV4 infection in MSM 
with AIDS removes the proposed link between immuno-
suppression and PARV4 detection. 
The  ﬁ   ndings of our study provide evidence that 
PARV4 is primarily or exclusively transmitted through 
parenteral routes, a marked contrast to predominantly re-
spiratory routes of transmission of parvoviruses in other 
genera, including B19 and human bocavirus (11). Although 
no information was provided on the speciﬁ  c risk factors for 
persons at high risk who were enrolled in the Options Proj-
ect cohort (i.e., whether an IDU or MSM), the ﬁ  nding of a 
higher prevalence of viremia in this group compared with 
blood donor controls (3) is also consistent with evidence 
obtained in the current study for a predominantly parenteral 
route of transmission. 
Previous observations of the remarkable sequence 
homogeneity of PARV4 nucleotide sequences between 
variants detected in the United Kingdom and in the United 
States (3,8) indicate the recent origin and spread of this vi-
rus in this speciﬁ  c risk group. Although we currently under-
stand little about its pathogenicity or the clinical outcome 
Table 1.  Detection of parvovirus B19 and PARV4 in study groups* 
Participant category (no.)  M/F
Age at death, y
(range)† 
Year of death 
(range)† 
Mean CD4/μL
(range)†  AIDS?
B19 positive,
no. (%) 
PARV4
positive, no. (%)
HIV+ IDU, AIDS‡ (13)  10/3 35 (2–48)  1995
(1991–1998) 
44
(1–137) 
Y  6 (46)  11 (85) 
HIV+ IDU, pre-AIDS‡ (11)  7/4 33 (29–40)  1996
(1992–1998) 
268
(167–496) 
N 6 (55)  6 (55) 
HIV+ MSM (13)  13/0 39 (28–49)  1993
(1990–1996) 
25
(1–160) 
Y 7  (54)  0
HIV– IDU (12)  10/2 35 (24–49)  1999
(1992–2005) 
ND NA 8 (67)  1 (8) 
Hemophilia (2)  2/0 22, 26  1994, 1995  0 Y  0 1 (50) 
Low-risk control§ (8)  3/5 54 (28–89)  All 2005  ND NA 8 (100)  0
*IDU, injection drug user; M, male; F, female; Y, yes; N, no; MSM, men who had sex with men; ND, not done; NA, not applicable. 
†Values are means  (ranges) or individual values for those with hemophilia. 
‡These study groups overlap with the previously analyzed HIV-positive group (8), restricted to those in whom parenteral risk factors for infection have 
been identified. 
§Previously described in (8). 
Table 2. Concordance of parvovirus B19 and PARV4 detection 
between bone marrow and lymphoid tissue* 
Lymphoid tissue 
Virus detected and risk group  Positive Negative
B19 (all risk groups) 
 Bone  marrow 
  Positive  27 1
  Negative  32 9
PARV4 (IDUs and persons with hemophilia) 
 Bone  marrow 
  Positive  14 1
  Negative  2 21
*IDUs, injection drug users. DISPATCHES
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of infection, PARV4 infection represents a potential newly 
emerging, additional bloodborne virus in IDUs. Given the 
resistance of parvoviruses to viral inactivation procedures, 
recipients of a wide range of plasma-derived therapeutics 
may also be at risk for PARV4 infection.
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